Literature DB >> 11122435

Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression.

D Cvejic1, S Savin, S Golubovic, I Paunovic, S Tatic, M Havelka.   

Abstract

AIMS: Galectin-3 is a beta-galactoside binding protein involved in multiple biological processes through interactions with complementary glycoconjugates. We analysed the expression and coexpression of galectin-3 and carcinoembryonic antigen (CEA), one of the putative galectin-3 ligands, in medullary thyroid carcinoma (MTC). METHODS AND
RESULTS: An immunohistochemical study using monoclonal antibodies was performed on paraffin sections of 20 cases of sporadic MTC comprising 10 cases without and 10 cases with lymph node metastases at the time of surgery. CEA expression was found in all tumours, distributed predominantly in the cytoplasm and occasionally at the cell surface. In the majority of cases (18/20) moderate to strong intensity of staining was found in most of the cells. Positive cytoplasmic staining for galectin-3 was found in 16/20 cases, but varied in intensity and distribution from weak/focal (7/16) to moderate (7/16) or strong (2/16). More intense staining for galectin-3 was mainly associated with MTC cases involving lymph node metastases. Eight out of these 10 cases showed moderate to strong galectin-3 expression concomitant with CEA expression throughout the tumour tissue.
CONCLUSIONS: These findings suggest that galectin-3 might play a role in the pathobiology of MTC. Simultaneous expression of galectin-3 and CEA in the same tumour cells at an advanced stage of MTC indicates the possibility of their autocrine cooperation during tumour progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122435     DOI: 10.1046/j.1365-2559.2000.00988.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 2.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

Review 3.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

4.  Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma.

Authors:  Milan Jovanovic; Nevena Gajovic; Natasa Zdravkovic; Marina Jovanovic; Milena Jurisevic; Danilo Vojvodic; Veljko Maric; Aleksandar Arsenijevic; Ivan Jovanovic
Journal:  Mediators Inflamm       Date:  2018-04-04       Impact factor: 4.711

Review 5.  Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.

Authors:  Salvatore Sciacchitano; Luca Lavra; Alessandra Morgante; Alessandra Ulivieri; Fiorenza Magi; Gian Paolo De Francesco; Carlo Bellotti; Leila B Salehi; Alberto Ricci
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

6.  Synergistic interaction between galectin-3 and carcinoembryonic antigen promotes colorectal cancer metastasis.

Authors:  Keng-Liang Wu; Eng-Yen Huang; Wen-Ling Yeh; Chang-Chun Hsiao; Chung-Mou Kuo
Journal:  Oncotarget       Date:  2017-06-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.